Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 3524
  • Home
  • Print this page
  • Email this page
Year : 2019  |  Volume : 67  |  Issue : 12  |  Page : 2075-2077

Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab

1 Department of Ophthalmology, Hospital, Madrid, Spain
2 Department of Rheumatology, Hospital, Madrid, Spain

Correspondence Address:
Mrs. Carmen Navarro-Perea
Street Doctor Esquerdo 166, Madrid - 28007, Spain
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijo.IJO_1161_19

Rights and Permissions

Pembrolizumab is a programmed cell death protein 1 (PD-1) monoclonal antibody used in the treatment of metastatic melanomas. Severe ocular complications appear in less than 1% of the patients and require early treatment. We present the case of a patient diagnosed with a BRAF mutated metastatic melanoma. Ocular pain and a blurred vision appeared after treatment and the patient visited the ophthalmology emergency room, where he was diagnosed with acute anterior uveitis (AAU), synechiae, and bilateral papillitis. The patient was treated with topical corticosteroids, prednisone, and mydriatics, which immediately improved the patient's status. Therefore, when an ocular inflammatory disease exists, immune checkpoint inhibitor treatments must be ruled out as possible causes.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded130    
    Comments [Add]    

Recommend this journal